About: Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
Creator	Burton, Dennis Schultz, Peter Chan, A Mcnamara, Case Rogers, Thomas Azhar, J Bakowski, Malina Beutler, Nathan Chatterjee, Arnab Chen, Emily Gupta, Anil Hui, E Hull, Mitchell Kirkpatrick, Melanie Nguyen, Tu-Trinh Parren, Mara Ricketts, James Yang, Linlin Yuen, D
Source	BioRxiv; WHO
abstract	The ongoing pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), necessitates strategies to identify prophylactic and therapeutic drug candidates for rapid clinical deployment. A high-throughput, high-content imaging assay of human HeLa cells expressing the SARS-CoV-2 receptor ACE2 was used to screen ReFRAME, a best-in-class drug repurposing library. From nearly 12,000 compounds, we identified 66 compounds capable of selectively inhibiting SARS-CoV-2 replication in human cells. Twenty-four of these drugs show additive activity in combination with the RNA-dependent RNA polymerase inhibitor remdesivir and may afford increased in vivo efficacy. We also identified synergistic interaction of the nucleoside analog riboprine and a folate antagonist 10-deazaaminopterin with remdesivir. Overall, seven clinically approved drugs (halofantrine, amiodarone, nelfinavir, simeprevir, manidipine, ozanimod, osimertinib) and 19 compounds in other stages of development may have the potential to be repurposed as SARS-CoV-2 oral therapeutics based on their potency, pharmacokinetic and human safety profiles.
has issue date	2020-06-16(xsd:dateTime)
bibo:doi	10.1101/2020.06.16.153403
has license	biorxiv
sha1sum (hex)	c6a9f858e7d66e7459e35a9d6bb049babc242a35
schema:url	https://doi.org/10.1101/2020.06.16.153403
resource representing a document's title	Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19
schema:publication	bioRxiv
resource representing a document's body	covid:c6a9f858e7d66e7459e35a9d6bb049babc242a35#body_text
is schema:about of	named entity 'identify' named entity 'osimertinib' named entity 'SARS-CoV-2' named entity 'RNA POLYMERASE INHIBITOR' named entity 'HUMAN CELLS' named entity 'THEIR' named entity 'OSIMERTINIB' named entity 'AMIODARONE' named entity 'EFFICACY' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'interaction' named entity 'repurposed' named entity 'ongoing' named entity 'imaging' named entity 'folate' named entity 'expressing' named entity 'remdesivir' named entity 'receptor' named entity 'potency' named entity '12,000' named entity 'therapeutic drug' named entity 'oral therapeutics' named entity 'manidipine' named entity 'approved drugs' named entity 'assay' named entity 'SARS-CoV-2' named entity 'high-throughput' named entity 'pharmacokinetic' named entity 'Clinical features' named entity 'coronavirus' named entity 'assay' named entity 'ACE2' named entity 'S1P1' named entity 'remdesivir' named entity 'influenza virus' named entity 'HEK293T' named entity 'Ebola' named entity 'mechanism of action' named entity 'SARS-CoV-2' named entity 'manidipine' named entity 'drug resistance' named entity 'hit selection' named entity 'infection' named entity 'DAPI' named entity 'simeprevir' named entity 'prodrug' named entity 'drug resistance' named entity 'live cells' named entity 'HeLa' named entity 'Thermo Fisher Scientific' named entity 'ozanimod' named entity 'transfection' named entity 'toxicity' named entity 'apilimod' named entity 'BD Biosciences' named entity 'apilimod' named entity 'small molecules' named entity 'primary and secondary antibody' named entity 'oncolytic' named entity 'representing the frequency' named entity 'dose response curves' named entity 'viral infection' named entity 'remdesivir' named entity 'liquid chromatography-mass spectrometry' named entity 'neglected tropical diseases' named entity 'long-term'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software